Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Baxter
Medtronic
McKinsey

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Aclarubicin


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Aclarubicin?

Aclarubicin is an investigational drug.

There have been 8 clinical trials for Aclarubicin. The most recent clinical trial was a Phase 1 trial, which was initiated on March 24th 2021.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Sun Yat-sen University, Jingjiang People's Hospital, and Second Affiliated Hospital of Soochow University.

There are six hundred and forty-one US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for Aclarubicin
TitleSponsorPhase
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLSun Yat-sen UniversityPhase 2
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive ChemotherapyShanghai Jiao Tong University School of MedicinePhase 2

See all Aclarubicin clinical trials

Clinical Trial Summary for Aclarubicin

Top disease conditions for Aclarubicin
Top clinical trial sponsors for Aclarubicin

See all Aclarubicin clinical trials

US Patents for Aclarubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Aclarubicin ⤷  Try it Free Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA) ⤷  Try it Free
Aclarubicin ⤷  Try it Free Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) ⤷  Try it Free
Aclarubicin ⤷  Try it Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Aclarubicin ⤷  Try it Free Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try it Free
Aclarubicin ⤷  Try it Free Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ⤷  Try it Free
Aclarubicin ⤷  Try it Free Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Aclarubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Aclarubicin Australia AU2014232383 2033-03-15 ⤷  Try it Free
Aclarubicin Australia AU2019202731 2033-03-15 ⤷  Try it Free
Aclarubicin Australia AU2019288275 2033-03-15 ⤷  Try it Free
Aclarubicin Brazil BR112015023267 2033-03-15 ⤷  Try it Free
Aclarubicin Brazil BR112020025927 2033-03-15 ⤷  Try it Free
Aclarubicin Canada CA2906931 2033-03-15 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Baxter
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.